The pan-PI3K inhibitors copanlisib (BAY 80–69460) and pilaralisib (XL-147) have also been shown to decrease PI3K activity in vitro, with the latter showing a significantly higher potency in PTEN-deficient prostate cancer cell lines [164,165]. Here, PTEN is linked to prostate carcinoma.